vs
Opendoor Technologies Inc.（OPEN）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Opendoor Technologies Inc.的1.0倍（$772.1M vs $736.0M），Revvity净利率更高（12.7% vs -148.9%，领先161.7%），Revvity同比增速更快（5.9% vs -32.1%），Revvity自由现金流更多（$161.8M vs $67.0M），过去两年Revvity的营收复合增速更高（9.0% vs -21.1%）
Opendoor Technologies Inc.是一家主营住宅房地产买卖的线上企业，总部位于旧金山。平台可通过线上流程向房主提供房屋即时现金报价，收购房产后进行修缮再重新挂牌出售，同时还提供基于移动端应用的购房服务及配套融资方案，截至2021年11月业务覆盖美国44个区域市场。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OPEN vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.0倍
$736.0M
营收增速更快
RVTY
高出38.0%
-32.1%
净利率更高
RVTY
高出161.7%
-148.9%
自由现金流更多
RVTY
多$94.8M
$67.0M
两年增速更快
RVTY
近两年复合增速
-21.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $736.0M | $772.1M |
| 净利润 | $-1.1B | $98.4M |
| 毛利率 | 7.7% | — |
| 营业利润率 | -20.4% | 14.5% |
| 净利率 | -148.9% | 12.7% |
| 营收同比 | -32.1% | 5.9% |
| 净利润同比 | -869.9% | 3.9% |
| 每股收益（稀释后） | $-1.42 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OPENRVTY
| Q4 25 | $736.0M | $772.1M | ||
| Q3 25 | $915.0M | $698.9M | ||
| Q2 25 | $1.6B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.1B | $729.4M | ||
| Q3 24 | $1.4B | $684.0M | ||
| Q2 24 | $1.5B | $691.7M | ||
| Q1 24 | $1.2B | $649.9M |
净利润OPENRVTY
| Q4 25 | $-1.1B | $98.4M | ||
| Q3 25 | $-90.0M | $46.7M | ||
| Q2 25 | $-29.0M | $53.9M | ||
| Q1 25 | $-85.0M | $42.2M | ||
| Q4 24 | $-113.0M | $94.6M | ||
| Q3 24 | $-78.0M | $94.4M | ||
| Q2 24 | $-92.0M | $55.4M | ||
| Q1 24 | $-109.0M | $26.0M |
毛利率OPENRVTY
| Q4 25 | 7.7% | — | ||
| Q3 25 | 7.2% | 53.6% | ||
| Q2 25 | 8.2% | 54.5% | ||
| Q1 25 | 8.6% | 56.5% | ||
| Q4 24 | 7.8% | — | ||
| Q3 24 | 7.6% | 56.3% | ||
| Q2 24 | 8.5% | 55.7% | ||
| Q1 24 | 9.7% | 54.6% |
营业利润率OPENRVTY
| Q4 25 | -20.4% | 14.5% | ||
| Q3 25 | -7.4% | 11.7% | ||
| Q2 25 | -0.8% | 12.6% | ||
| Q1 25 | -4.9% | 10.9% | ||
| Q4 24 | -8.7% | 16.3% | ||
| Q3 24 | -4.9% | 14.3% | ||
| Q2 24 | -4.8% | 12.4% | ||
| Q1 24 | -7.4% | 6.8% |
净利率OPENRVTY
| Q4 25 | -148.9% | 12.7% | ||
| Q3 25 | -9.8% | 6.7% | ||
| Q2 25 | -1.9% | 7.5% | ||
| Q1 25 | -7.4% | 6.4% | ||
| Q4 24 | -10.4% | 13.0% | ||
| Q3 24 | -5.7% | 13.8% | ||
| Q2 24 | -6.1% | 8.0% | ||
| Q1 24 | -9.2% | 4.0% |
每股收益（稀释后）OPENRVTY
| Q4 25 | $-1.42 | $0.86 | ||
| Q3 25 | $-0.12 | $0.40 | ||
| Q2 25 | $-0.04 | $0.46 | ||
| Q1 25 | $-0.12 | $0.35 | ||
| Q4 24 | $-0.16 | $0.77 | ||
| Q3 24 | $-0.11 | $0.77 | ||
| Q2 24 | $-0.13 | $0.45 | ||
| Q1 24 | $-0.16 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $962.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.0B | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OPENRVTY
| Q4 25 | $962.0M | $919.9M | ||
| Q3 25 | $962.0M | $931.4M | ||
| Q2 25 | $789.0M | $991.8M | ||
| Q1 25 | $559.0M | $1.1B | ||
| Q4 24 | $679.0M | $1.2B | ||
| Q3 24 | $837.0M | $1.2B | ||
| Q2 24 | $809.0M | $2.0B | ||
| Q1 24 | $990.0M | $1.7B |
股东权益OPENRVTY
| Q4 25 | $1.0B | $7.3B | ||
| Q3 25 | $811.0M | $7.4B | ||
| Q2 25 | $631.0M | $7.6B | ||
| Q1 25 | $645.0M | $7.6B | ||
| Q4 24 | $713.0M | $7.7B | ||
| Q3 24 | $801.0M | $7.9B | ||
| Q2 24 | $845.0M | $7.9B | ||
| Q1 24 | $899.0M | $7.8B |
总资产OPENRVTY
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $2.7B | $12.1B | ||
| Q2 25 | $2.9B | $12.4B | ||
| Q1 25 | $3.3B | $12.4B | ||
| Q4 24 | $3.1B | $12.4B | ||
| Q3 24 | $3.4B | $12.8B | ||
| Q2 24 | $3.4B | $13.4B | ||
| Q1 24 | $3.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $70.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $67.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 9.1% | 21.0% |
| 资本支出强度资本支出/营收 | 0.4% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.0B | $509.4M |
8季度趋势，按日历期对齐
经营现金流OPENRVTY
| Q4 25 | $70.0M | $182.0M | ||
| Q3 25 | $435.0M | $138.5M | ||
| Q2 25 | $823.0M | $134.3M | ||
| Q1 25 | $-279.0M | $128.2M | ||
| Q4 24 | $-80.0M | $174.2M | ||
| Q3 24 | $62.0M | $147.9M | ||
| Q2 24 | $-399.0M | $158.6M | ||
| Q1 24 | $-178.0M | $147.6M |
自由现金流OPENRVTY
| Q4 25 | $67.0M | $161.8M | ||
| Q3 25 | $432.0M | $120.0M | ||
| Q2 25 | $821.0M | $115.5M | ||
| Q1 25 | $-283.0M | $112.2M | ||
| Q4 24 | $-83.0M | $149.8M | ||
| Q3 24 | $56.0M | $125.6M | ||
| Q2 24 | $-407.0M | $136.6M | ||
| Q1 24 | $-186.0M | $129.7M |
自由现金流率OPENRVTY
| Q4 25 | 9.1% | 21.0% | ||
| Q3 25 | 47.2% | 17.2% | ||
| Q2 25 | 52.4% | 16.0% | ||
| Q1 25 | -24.5% | 16.9% | ||
| Q4 24 | -7.7% | 20.5% | ||
| Q3 24 | 4.1% | 18.4% | ||
| Q2 24 | -26.9% | 19.7% | ||
| Q1 24 | -15.7% | 20.0% |
资本支出强度OPENRVTY
| Q4 25 | 0.4% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.1% | 2.6% | ||
| Q1 25 | 0.3% | 2.4% | ||
| Q4 24 | 0.3% | 3.4% | ||
| Q3 24 | 0.4% | 3.3% | ||
| Q2 24 | 0.5% | 3.2% | ||
| Q1 24 | 0.7% | 2.7% |
现金转化率OPENRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OPEN
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
